NuRAN Wireless Inc. (CSE:NUR,FWB:1RN,OTCMKTS:NRRWF) (“NuRAN Wireless” or the “Company”), a leading supplier of mobile and broadband wireless infrastructure solutions announces the introduction of its Mobile Network Enabler (“MNE”) business model. The new model will facilitate network rollouts for mobile network operators by providing them with a zero-CAPEX model where NuRAN provides its mobile network solutions as a service.
TORONTO, Oct. 10, 2018 /CNW/ – Enforcer Gold Corp (“Enforcer” or the “Company”) (TSX-V: VEIN – FSE: N071) is pleased to announce that the second phase of diamond drilling on the Roger project is set to resume this week. The program is designed to build on the results from the pit-constrained mineral resource estimate announced on September 18, 2018, which confirmed the strong potential of the MOP-II deposit. The Roger project is located 5 km from the historic mining center of Chibougamau, Quebec, has all-season road access and is crossed by a power line that serviced the past-producing Troilus Mine.
FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that construction has commenced of its heritage museum and flagship dispensary at the former Kraft plant in Cobourg, Ontario, headquarters of its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”). Local politicians and media will be in attendance at the ribbon-cutting ceremony on October 9, 2018 at 11:30 EST in Cobourg at the Head office located at 520 William Street. Honoured invited guests include Cobourg Mayor Gil Brocanier who will be in attendance and the Hon. Kim Rudd, MP for Northumberland and Peterborough South who is expected to attend. All national media are welcome with media credentials.
TORONTO, Oct. 04, 2018 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (TSXV: EGLX) (“Enthusiast” or the “Company”), a digital media company building the largest community of authentic gamers, today announces that its shares will begin trading when markets open, at 9:30am EDT, on October 4, 2018 on the TSX Venture Exchange (the “Exchange”). As previously announced (See press release dated September 24, 2018), Enthusiast —formerly Tova Ventures II, Inc. (TSX.V: TOVA.P) will trade under the stock ticker symbol “EGLX.”
CALGARY, Oct. 3, 2018 /CNW/ – High Tide Ventures Inc. (“High Tide” or the “Company”) announced that yesterday it closed the second tranche of a brokered private placement offering (the “Offering”), pursuant to which the Company issued in aggregate 13,307,418 special warrants at a price of $1.38 per special warrant for gross proceeds of $18,364,237. The Offering was upsized by over 83% from an original amount of $10,000,000 due to strong demand from over 135 participating investors. Canaccord Genuity Corp. was the sole lead manager and sole lead bookrunner and the syndicate also included Mackie Research Capital Corporation and Laurentian Bank Securities Inc. The selling group consisted of GMP Securities and Raymond James Ltd.
TORONTO, Sept. 25, 2018 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE:PILL) (“Canntab”), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment.
TORONTO, Sept. 23, 2018 FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), focused on the cardiovascular disease field. The new research program is aimed at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world.
